Darwin Research Group

Darwin Research Group provides advanced market intelligence and strategic insights to executives in pharmaceutical, medical device, health systems, venture capital/private equity firms and other healthcare investors[1][2][4]. They specialize in analyzing healthcare delivery models (including integrated health systems and physician groups), payer models (such as ACOs and bundled payments), oncology networks, value-based care trends, and customer profiling for life sciences companies[1][2].

They do not conduct clinical trials or have a therapeutic pipeline.

Their proprietary research includes deep dives into IDNs (Integrated Delivery Networks), cancer centers/oncology-focused groups, post–acute care providers and emerging payment models[2].

The firm was founded by John Marchica in 2010 after his previous experience with FaxWatch[1]. It operates from Scottsdale AZ (HQ) and Princeton NJ[1][4].

Darwin’s clients include pharmaceutical companies seeking to understand evolving healthcare ecosystems for business strategy purposes.

No information suggests they are involved in drug discovery/development or own any therapeutic assets.

Their estimated revenue ranges from $1M–$7M annually with fewer than 50 employees[4][5][7].

They are recognized as an Inc. 5000 honoree for growth but are not public nor acquired by another entity[3].

Key person listed is founder/CEO John Marchica.

No evidence of academic collaborations or licensing activity.

No manufacturing capabilities—company focus remains on research/consulting services.

Pipeline-related fields below are left blank/not applicable due to business model.